Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Biogen Idec Advises Use Of Avonex Powder Formulation To Prevent Shortage

This article was originally published in The Pink Sheet Daily

  • News
  • ­ Steele Thomas

Executive Summary

An April 29 Dear Health Care Professional letter says Biogen Idec “may experience” a shortage of the liquid formulation of the MS therapy due to manufacturing impurity issues.

You may also be interested in...



Avonex Manufacturing Update: New Liquid Fill-Finish Process Validated

Biogen Idec has completed validation of a new fill-finish process for the liquid formulation of Avonex.

Avonex Manufacturing Update: New Liquid Fill-Finish Process Validated

Biogen Idec has completed validation of a new fill-finish process for the liquid formulation of Avonex.

Biogen Addressing Avonex Liquid Formulation Manufacturing Problems

Pre-filled syringe process is experiencing a "technical issue" on the fill-finish side. Biogen has the option to ramp up production of Avonex' original lyophilized powder formulation to make up for shortages on the liquid side.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS059580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By